Aberdeen-based biotech Elasmogen is to collaborate with London-based Intract Pharma to develop medical treatments, firstly for inflammatory bowel disease.
The two businesses have signed an agreement to jointly develop novel orally delivered protein therapeutics.
The new treatments will incorporate proprietary technologies developed by each of the partners.
The collaboration will combine Elasmogen's soloMER technology with Interact's Soteria and Phloral technologies, a unique platform for oral delivery of biologics targeted to the lower gastrointestinal (GI) tract.
The aim is to combine the advantages of these platforms to allow the oral delivery of therapeutically active, highly potent and gut targeted proteins, initially focused on local GI indications such as inflammatory bowel disease.
Elasmogen CEO Caroline Barelle said “Achieving oral delivery of our soloMER products is a key differentiator for our technology and I am delighted that following very encouraging proof of concept studies with Intract’s Soteria technology we can now announce this extended and accelerating collaboration.”
Bill Lindsay, CEO of Intract, said “Collaboration with Elasmogen represents an exciting synergy of Intract’s expertise in the formulation of biologic drugs with Elasmogen’s unique multi-valent formats to allow the development of novel and potent oral therapeutics”.
